Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending May 9, 2020

5/12/2020

 
Regulatory Update
 
The FDA approved selpercatinib (Retevmo, Lilly) on 5/8/2020, for the treatment of non-small cell lung cancer, advanced medullary thyroid cancer and advanced RET fusion-positive thyroid cancer. The FDA requires identification of a RET gene alteration must be determined before initiating treatment. Selpercatinib is taken twice a day until the disease progresses or there is unacceptable toxicity. Lilly set WAC for a 30-day supply of selpercatinib at $20,600. Selpercatinib is the first drug approved to treat cancers with mutation or fusion in the RET gene, but the drug will eventually have competition from pralsetinib, a second RET fusion mutation therapy from Blueprint Medicines. Blueprint filed an NDA for pralsetinib in 1Q2020, so a competitor for selpercatinib may be available in late 2020 or early 2021.
 
The FDA approved capmatinib (Tabrecta, Novartis) on 5/6/2020, for the treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Novartis has set WAC for a 28-day supply of capmatinib at $17,950. Capmatinib is the first drug approved to treat cancers with MET exon 14 skipping alterations.  The drug will eventually have competition from tepotinib, a MET inhibitor being developed by EMD Serono.
 
The FDA accepted the NDA for Bristol-Myers Squibb/Juno/Therapeutics Celgene’s lisocabtagene maraleucel for the treatment of large B-cell lymphoma and set a PDUFA date for August 2020. The PDUFA date was then delayed by three months in May 2020 to allow the FDA time to review new requested data for the drug. The new PDUFA date is 11/16/2020.
 
The FDA granted Amgen/Cytokinetics’ omecamtiv mecarbil, Fast Track designation as a treatment of chronic heart failure with reduced ejection fraction (HFrEF).
 
The EMA granted Acceleron Pharma’s sotatercept a Priority Medicines (PRIME) designation for the treatment of patients with pulmonary arterial hypertension (PAH).
 
Announced Research Updates
 
TG Therapeutics announced interim data from the 420 patient, Phase III UNITY-CLL trial, where patients treated with ublituximab plus umbralisib had an improved progression free survival compared to obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). Due to the results, the trial was ended early.
 
Akebia announced that in the 36-week, 369 patient, Phase III, INNO2VATE Correction/Conversion trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin (0.17 g/dL difference) and hemoglobin level (10.36 vs 10.53 g/dL) in patients with chronic dialysis for end-stage renal disease. Akebia announced that in the 36-week, 3,554 patient, Phase III, INNO2VATE Conversion trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin (0.31 g/dL difference) and hemoglobin level (10.36 vs 10.61 g/dL) in patients with chronic dialysis for end-stage renal disease. In the two INNO2VATE Correction/Conversion and Conversion trials, vadadustat was non-inferior to darbepoetin in the incidence of MACE (composite endpoint of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke).
 
Ovid announced that in the 12-week, 23 patient, Phase II ROCKET trial, treatment with gaboxadol resulted in a 26.2% improvement in the Aberrant Behavior Checklist-Community for Fragile X syndrome (ABC-CFXS) score and a 21.6% mean improvement in the Anxiety, Depression and Mood Scale (ADAMS) total score in patients with Fragile X syndrome.
 
Published Research Updates
 
In a 65 patient, Phase II trial, patients treated with voxtalisib plus pimasertib, the objective response rate (ORR) was 9.4% compared to 12.1% with pimasertib monotherapy in patients with recurrent unresectable borderline/low malignant potential or low-grade serous ovarian carcinoma. The trial was terminated early because over half of the patients in both arms discontinued treatment and the ORR was considered too low. 
 
In the 150 patient, Japanese PELTA trial, prophylactic landiolol for four days after surgery did not reduce the incidence of postoperative atrial fibrillation in post-cardiac surgery patients who were 70 years or older.
 
In a 12-week, 257 patient, Phase II trial, treatment with estetrol 15 mg decreased the severity of hot flushes (HFs) compared to placebo (-1.04 vs -0.66) in postmenopausal women with seven or more moderate to severe HFs per day or 50 or more moderate to severe HFs weekly.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.